Effects of ciltacabtagene autoleucel injection: A Synthesis of Findings from 7 Studies

  1. Home
  2. Effects of ciltacabtagene autoleucel injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ciltacabtagene autoleucel injection: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ciltacabtagene autoleucel injection: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Cilostazol, a phosphodiesterase III inhibitor, has shown promise in various cardiovascular applications. 6 highlights its vasodilating and antiplatelet properties, which make it useful for improving intermittent claudication in patients with peripheral artery disease (PAD). Cilostazol also demonstrated effectiveness in patients undergoing percutaneous revascularization procedures for both PAD and coronary artery disease. 4 found that cilostazol, due to its pleiotropic effects, can potentially be beneficial for both coronary artery disease and PAD. It is also potentially useful after ischemic stroke and serves as an alternative for patients allergic or intolerant to conventional antithrombotic agents. 3 found that Cilostazol may help prevent cerebrovascular, cardiac, and vascular events, and reduce major hemorrhagic events. 2 found that Cilostazol can improve lipid and fatty acid metabolism, which may be helpful for preventing atherosclerosis. 7 found that cilostazol has potent antiatherosclerotic effects and can even reverse atherosclerosis progress in high-risk patients, such as those with type 2 diabetes mellitus. 1 found that cilostazol was generally well tolerated and could be used as an alternative treatment for patients with intermittent claudication. 5 found that cilostazol may increase heart rate in patients who have undergone drug-eluting stent implantation.

Benefits and Risks

Benefits Summary

Cilostazol can help improve symptoms of intermittent claudication in patients with PAD, and may be beneficial for patients undergoing percutaneous revascularization procedures. 6 It can also help prevent atherosclerosis, improve lipid and fatty acid metabolism, and may be a good alternative for those who cannot tolerate conventional antithrombotic medications. 2 7

Risk Summary

Cilostazol may cause side effects, including headaches, diarrhea, abnormal stools, infections, rhinitis, and peripheral edema. 1 It can also interact with other medications, particularly those that inhibit CYP3A4 or CYP2C19. 1 It may increase heart rate in some patients. 5 It is important to discuss cilostazol with your doctor and understand the potential risks and benefits before starting treatment.

Comparison of Studies

Commonalities

Multiple studies consistently demonstrate that cilostazol is effective in improving intermittent claudication in patients with PAD. 6 1 Cilostazol has been found to have vasodilating and antiplatelet properties with a low risk of bleeding complications. 6

Differences

Research findings regarding the effectiveness and safety of cilostazol can vary. 4 found that cilostazol may not prevent neurological deterioration from perforating artery infarction. However, other studies suggest that it may reduce the risk of stroke. 3 5 found that cilostazol may increase heart rate after drug-eluting stent implantation, while other studies report that it is generally well-tolerated. 1

Consistency and Inconsistencies

While several studies consistently show that cilostazol is beneficial for treating intermittent claudication in patients with PAD, there are inconsistencies regarding its other effects. 4 , 3 , 5 , 1 Further research is needed to clarify the potential benefits and risks of cilostazol for various conditions.

Practical Applications and Considerations

Cilostazol can be considered as a treatment option for improving intermittent claudication in patients with PAD. 6 1 It might also be beneficial for patients who have undergone percutaneous revascularization procedures. 6 However, cilostazol can cause side effects and interact with other medications. 1 It might also increase heart rate in some patients. 5 It is crucial to consult your doctor before starting cilostazol treatment to discuss your individual health conditions and risks.

Limitations of Current Research

Some studies on the effectiveness and safety of cilostazol have limitations, such as small sample sizes and a lack of long-term data. Research on the effects of cilostazol in specific patient populations is also limited. 4 , 5 , 3 , 2 , 7 , 1

Future Research Directions

Large-scale randomized controlled trials are needed to assess the long-term effects and safety of cilostazol. More research is also required to understand the effects of cilostazol in specific patient populations. 4 , 5 , 3 , 2 , 7 , 1 Further investigation into cilostazol's potential for stroke prevention and its impact on heart rate in various situations is also crucial.

Conclusion

Cilostazol shows promise as a treatment option for improving intermittent claudication in patients with PAD. 6 1 It has vasodilating and antiplatelet properties with a low risk of bleeding complications. 6 1 However, it is important to remember that cilostazol can cause side effects and may interact with other medications. 5 It is essential to consult your doctor before starting cilostazol treatment to discuss your individual needs and potential risks. 4 , 3 , 2 , 7

Literature analysis of 7 papers
Positive Content
5
Neutral Content
1
Negative Content
1
Article Type
3
3
2
2
7
1.

Cilostazol: a review of its use in intermittent claudication.

Author: ChapmanTherese M, GoaKaren L

Intermittent claudication treatment
Quality of life improvement
Abnormal stools
Diarrhea
Drug interactions
Headache
Infection
Palpitations
Peripheral edema
Rhinitis

Cilostazol is a medication used to treat intermittent claudication. It is generally well tolerated, but may interact with other medications that inhibit cytochrome P450 3A4 or 2C19.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Effects of cilostazol on lipid and fatty acid metabolism.

Author: NakamuraN, OsawaH, YamabeH, OkumuraK, HamazakiT

Improved fatty acid composition
Improved serum lipid profile
Increased walking distances

Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. It significantly increased walking distances in patients with intermittent claudication compared with placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials.

Author: UchiyamaShinichiro, DemaerschalkBart M, GotoShinya, ShinoharaYukito, GotohFumio, StoneWilliam M, MoneySamuel R, KwonSun Uck

Cerebrovascular event prevention
Hemorrhagic events

Cilostazol is an antiplatelet agent that inhibits phosphodiesterase III in platelets and vascular endothelium. It has been studied for the prevention of cerebrovascular events, but the results have been mixed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

4.

Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory.

Author: KondoRyushi, MatsumotoYasushi, FuruiEisuke, ItabashiRyo, SatoShoichiro, YazawaYukako, ShimizuHiroaki, FujiwaraSatoru, TakahashiAkira, TominagaTeiji

Cilostazol efficacy
Perforating artery infarction

This prospective, randomized, open-label, blinded-end point trial examined the efficacy of cilostazol for the treatment of acute perforating artery infarction. Cilostazol did not prevent neurological deterioration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease.

Author: KwonBeom-June, LeeSu-Hyun, KimDong-Bin, ParkHun-Jun, JangSung-Won, IhmSang-Hyun, KimHee-Yeol, SeungKi-Bae

Increased heart rate

Cilostazol, when added to dual antiplatelet therapy, was found to increase heart rate in patients who received intracoronary drug-eluting stents. This effect was observed as early as six months after the stent implantation.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.

Author: ManolisAntonis A, ManolisTheodora A, MelitaHelen, MikhailidisDimitri P, ManolisAntonis S

Antiplatelet effect
Improved claudication
Reduced bleeding
Reduced restenosis
Stroke prevention
Vasodilation

Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications. The study reviews the accumulated evidence of cilostazol's benefits for treating both coronary artery disease and peripheral artery disease (PAD), including its potential use after ischemic stroke.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials.

Author: WanHongbing, HuangTieqiu, YangPingping, WuTao, ZhangHongzhou, WuQinghua

Atherosclerosis treatment
Improved lipid profile
Reduced carotid intima-media thickness
Headache

This meta-analysis of 10 randomized clinical trials found that cilostazol significantly reduced carotid intima-media thickness and had antiatherosclerotic effects without increasing the risk of bleeding.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.